![一种抗CD24人源化抗体融合蛋白](/CN/2017/1/110/images/201710554362.jpg)
基本信息:
- 专利标题: 一种抗CD24人源化抗体融合蛋白
- 专利标题(英):Anti-CD24 (cluster of differentiation 24) humanized antibody fusion protein
- 申请号:CN201710554362.9 申请日:2017-07-05
- 公开(公告)号:CN107226866A 公开(公告)日:2017-10-03
- 发明人: 王旻 , 张娟 , 孙福谋 , 杜晓典
- 申请人: 中国药科大学
- 申请人地址: 江苏省南京市江宁区龙眠大道639号
- 专利权人: 中国药科大学
- 当前专利权人: 中国药科大学
- 当前专利权人地址: 江苏省南京市江宁区龙眠大道639号
- 主分类号: C07K19/00
- IPC分类号: C07K19/00 ; A61K39/00 ; A61K47/68 ; A61P35/00
The invention belongs to the technical field of genetic engineering antibodies, and in particular relates to a preparation method and application of CD24 (cluster of differentiation 24) antibody fusion protein. A CD24 humanized antibody hG7S is connected with MICA (major histocompatibility complex class I chain-related gene A) molecule extracellular 1 to 3 domains through a G4S flexible peptide by utilizing a genetic engineering technology; an hG7S-MICA is stably expressed through a mammal eukaryotic expression system; CD24 humanized antibody hG7S-MICA fusion protein can be combined with a CD24 molecule on the surface of a tumor cell and an activated receptor NKG2D on the surface of an NK cell at the same time, and an immunologic surveillance effect of the NK cell induced by an NKG2D way on a CD24+tumor cell is rebuilt; finally, the aim of activating an organism self-immune system to effectively kill the CD24+tumor cell is realized.